Evidence map›Paper›PMID 28687044›Full record

ArticleDrug delivery2017

Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma.

Yue Zhang, Meifang Zhai, Zhijiang Chen, Xiaoyang Han, Fanglin Yu, Zhiping Li, Xiangyang Xie, Cuiyan Han, Lian Yu, Yang Yang and 1 more

Abstract read
In one paragraph

Article in Drug delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Nanotherapeutic Heterogeneity: Sources, Effects, and Solutions.Small (Weinheim an der Bergstrasse, Germany) · 2024
    Review
  14. Review
  15. Review
  16. Liposomal Nanomaterials: A Rising Star in Glioma Treatment.International journal of nanomedicine · 2024
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yue Zhanga State key Laboratory of Toxicology and Medical Countermeasure, Department of Pharmaceutics , Beijing Institute of Pharmacology and Toxicology , Beijing , PR China.
Meifang Zhaia State key Laboratory of Toxicology and Medical Countermeasure, Department of Pharmaceutics , Beijing Institute of Pharmacology and Toxicology , Beijing , PR China.
Zhijiang Chena State key Laboratory of Toxicology and Medical Countermeasure, Department of Pharmaceutics , Beijing Institute of Pharmacology and Toxicology , Beijing , PR China.
Xiaoyang Hand Outpatient Department of Beijing Space City , Aerospace Systems Divison, PLA Strategic Support Force , Beijing , PR China.
Fanglin Yua State key Laboratory of Toxicology and Medical Countermeasure, Department of Pharmaceutics , Beijing Institute of Pharmacology and Toxicology , Beijing , PR China.
Zhiping Lia State key Laboratory of Toxicology and Medical Countermeasure, Department of Pharmaceutics , Beijing Institute of Pharmacology and Toxicology , Beijing , PR China.
Xiangyang Xiee Department of Pharmacy , Wuhan General Hospital of the Chinese People's Liberation Army , Wuhan , PR China.
Cuiyan Hanf School of Pharmacy , Qiqihar Medical University , Qiqihar , PR China.
Lian Yuc Jiamusi University , Jiamusi , PR China.
Yang Yanga State key Laboratory of Toxicology and Medical Countermeasure, Department of Pharmaceutics , Beijing Institute of Pharmacology and Toxicology , Beijing , PR China.
Xingguo Meia State key Laboratory of Toxicology and Medical Countermeasure, Department of Pharmaceutics , Beijing Institute of Pharmacology and Toxicology , Beijing , PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic outcome for the treatment of glioma was often limited due to drug resistance and low permeability of drug across the multiple physiological barriers, including the blood-brain barrier (BBB), and the blood-tumor barrier (BTB). In order to overcome these hurdles, we designed T7 and

Indexed as

GliomaBrain NeoplasmsCell Line, TumorDoxorubicinDrug Delivery SystemsHumansLiposomesVascular Endothelial Growth Factor AVincristineDoxorubicinLiposomesVascular Endothelial Growth Factor AVincristinebrain targeted drug deliveryDA7R peptidedoxorubicingliomaT7 peptidevincristine

Identifiers

PMID28687044
PMCPMC8240983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.